Guardant Health Investor Presentation

LUNAR- 2: Addressing need for improved early cancer detection Pilot data has demonstrated strong performance in early detection of lung cancer LUNAR-2 Lung Sensitivity by Stage Sensitivity at around 98% specificity 100% 80% 60% 40% 20% 0% STAGE 1 STAGE 2 Note: The pilot data presented here may be impacted by small sample sizes, non-ideally matched and unblinded controls, and potentially other confounding factors. Further studies are required to verify the presented performance. 25 GUARDANT™

View entire presentation